Raloxifene Augmentation in Patients With a Schizophrenia Spectrum Disorder

PHASE3CompletedINTERVENTIONAL
Enrollment

110

Participants

Timeline

Start Date

August 31, 2016

Primary Completion Date

July 1, 2021

Study Completion Date

July 1, 2021

Conditions
SchizophreniaSchizoaffective DisorderSchizophreniform DisorderPsychosis NOS
Interventions
DRUG

Raloxifene

Oral selective estrogen receptor modulator (SERM).

DRUG

Placebo

Tablets identical in form and color to intervention.

Trial Locations (1)

3508GA

UMC Utrecht, Utrecht

All Listed Sponsors
collaborator

Julius Center

OTHER

collaborator

Rudolf Magnus Institute - University of Utrecht

OTHER

collaborator

GGZ Eindhoven

OTHER

collaborator

Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)

OTHER

collaborator

GGZ Centraal

OTHER

collaborator

Altrecht GGZ

UNKNOWN

collaborator

Reinier van Arkel Group

UNKNOWN

collaborator

Ziekenhuis Netwerk Antwerpen (ZNA)

OTHER

lead

Iris Sommer

OTHER

NCT03043820 - Raloxifene Augmentation in Patients With a Schizophrenia Spectrum Disorder | Biotech Hunter | Biotech Hunter